A method is provided for detecting a biological analyte in a medium. The method includes enclosing a catalyst in an encapsulate that includes an associated binder; adding reactants to the medium, followed by adding the encapsulate that contains the encapsulate to the medium. In response to presence of the analyte in the medium, the binder attaches to the analyte and opens the encapsulate to release the catalyst. The catalyst accelerates chemical change of the reactants into products. The method continues by detecting the products to register presence of the analyte.

The present invention relates to a method for capturing a molecular target present in the aqueous phase of a water-in-oil emulsion, said method being based on the use of a binding system comprising (a) a surfactant bearing a functional moiety on its hydrophilic head group and (b) a chemoprobe that acts as a molecular staple between the functionalized surfactant and the molecular target and comprises at least two distinct domains namely (i) at least one capture moiety which is able to specifically bind the molecular target and (ii) at least one binding domain which is able to interact with the functional group of the surfactant through covalent or non-covalent interactions, directly or through a binding intermediary.

The invention provides for a microfluidic droplet-based assay process and apparatus, wherein the process comprises the step of creating several assay droplets (18) containing paramagnetic particles (22, 22′), detectable markers (24), and at least one biological cell (10), wherein the paramagnetic particles (22, 22′) and the detectable markers (24) are able to bind with a target analyte (16) released by the cell, wherein the process includes storing several assay droplets along a horizontal storage plane, includes the generation of a magnetic field through the stored assay droplets, and includes detecting a physical characteristic of the detectable markers contained in a given assay droplet by optical imaging of the detectable markers, characterized in that the generation of a magnetic field generates a magnetic field such that the paramagnetic particles are attracted towards a lateral and inferior portion of the given stored assay droplet in which they are contained.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.

The present invention relates to a test element for the detection of an analyte comprising an enzyme, wherein the enzyme is incorporated in a nanocapsule.

The present invention describes methods of identifying drugs for the treatment or prevention of diabetes by measuring the activity of the human zinc transporter ZnT8 and pharmaceutical compositions.